Related Experiment Video
Updated: Jul 4, 2025
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
Published on: June 17, 2015
APOE2 Heterozygosity Reduces Hippocampal Soluble Amyloid-β42 Levels in Non-Hyperlipidemic Mice
Ana C Valencia-Olvera1, Deebika Balu1, Annabelle Moore2
1Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA.
Abstract:
APOE2 lowers Alzheimer's disease (AD) risk; unfortunately, the mechanism remains poorly understood and the use of mice models is problematic as APOE2 homozygosity is associated with hyperlipidemia. In this study, we developed mice that are heterozygous for APOE2 and APOE3 or APOE4 and overexpress amyloid-β peptide (Aβ) (EFAD) to evaluate the effect of APOE2 dosage on Aβ pathology. We found that heterozygous mice do not exhibit hyperlipidemia. Hippocampal but not cortical levels of soluble Aβ42 followed the order E2/2FAD > E2/3FAD≤E3/3FAD and E2/2FAD > E2/4FAD < E4/4FAD without an effect on insoluble Aβ42. These findings offer initial insights on the impact of APOE2 on Aβ pathology.
Insights
Apolipoprotein E2 (APOE2) may reduce Alzheimer's disease risk. New mice models show APOE2 dosage impacts amyloid-beta pathology without causing hyperlipidemia, offering insights into Alzheimer's disease mechanisms.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Apolipoprotein E2 (APOE2) is associated with reduced Alzheimer's disease (AD) risk, but its underlying mechanisms are unclear.
- Existing mouse models for studying APOE2's role in AD are limited due to APOE2 homozygosity causing hyperlipidemia.
Purpose of the Study:
- To investigate the effect of APOE2 dosage on amyloid-beta (Aβ) pathology in a novel mouse model.
- To assess whether heterozygous APOE2 expression in mice leads to hyperlipidemia.
Main Methods:
- Developed genetically engineered mice expressing human APOE2, APOE3, or APOE4 alleles, alongside amyloid-beta peptide (Aβ) overexpression (EFAD mice).
- Assessed hyperlipidemia and measured soluble and insoluble Aβ42 levels in hippocampal and cortical tissues.
Main Results:
- Heterozygous APOE2 mice (E2/3FAD, E2/4FAD) did not develop hyperlipidemia.
- Soluble Aβ42 levels in the hippocampus showed a dosage-dependent effect, with E2/2FAD > E2/3FAD ≤ E3/3FAD and E2/2FAD > E2/4FAD < E4/4FAD.
- No significant effect on insoluble Aβ42 levels was observed across genotypes.
Conclusions:
- Heterozygous APOE2 expression in mice is viable for studying AD pathology without inducing hyperlipidemia.
- APOE2 dosage influences soluble Aβ42 levels in the hippocampus, providing new insights into its protective role against Alzheimer's disease.
More Related Videos
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016